Antitrust Filing in 202X M&A: Case Study

The antitrust filing process in M&A isn’t a hidden lever; it’s a gate that can shape deal structure, timing, and even the decision to move forward. From my vantage as a compliance analyst, the facts are clear: pre-merger notifications under the Hart-Scott-Rodino Act set the baseline for how regulators view overlap, market definition, and potential harm. In FY 2024, the U.S. antitrust regime cleared 184 transactions, about 9.0% of HSR filings, and issued 59 second requests. That is not a noise level; it’s a signal that many deals will be reviewed with questions that can slow or reshape. We must take into consideration that 2,031 HSR filings were reported in FY 2024, up from 1,805 in the prior year, and around 25% of those deals were valued at $1 billion or more. The threshold itself moved to $126.4 million effective February 21, 2025, with a filing fee of $30,000 for transactions in the $126.4 to $179.4 million range. These shifts aren’t cosmetic; they change deal calculus for middle-market buyers and PE shops alike.

I would say that the core driver in 2025 remains the balance between keeping transactions on track and addressing substantive competitive concerns early. The Trump administration’s tilt toward settlements continued in 2025 (but regulators did not stop policing divestiture remedies or structural concessions). In practice, that means licensing or divestiture remedies are increasingly part of the closure playbook, not a postscript. The data supports that: in FY 2024, DOJ and FTC pursued 32 enforcement actions (1.6% of transactions), leading to abandonments or restructurings, and noteworthy settlements or actions continued through 2025, including cases that reached divestitures or corrective measures before closing.

Let’s anchor this with real-world examples that matter for deal teams. UnitedHealth’s acquisition of Amedisys moved through a DOJ lens and ended with divestitures required to address home health and hospice overlap. The settlement included divestitures across 164 locations in 19 states, which illustrates how a regulator’s concern about care delivery markets translates into concrete operational remedies.

Amedisys also faced an HSR civil penalty of $1.1 million in that matter, underscoring that even routine filings carry risk if reporters miss thresholds or miscalculate assets or potential HSR triggers. For dealmakers, the UnitedHealth/Amedisys case demonstrates that the remedy path can be a central gating item in the closing checklist, not a post-closing footnote.

On the technology and services side, the HPE/Juniper case and the Keysight/Spirent matter show how divestitures and asset carve-outs shape both strategic alignment and post-merger integration. In the HPE/Juniper deal, the DOJ settled with a divestiture of HPE’s Instant On business. In the Keysight/Spirent matter, a DOJ case opened on June 2, 2025, and was settled with divestitures of Ethernet and security testing businesses. These outcomes reflect a broader pattern: regulators are willing to approve deals with targeted divestitures that preserve competition in specific product lines or markets, especially in high-velocity tech ecosystems where cross-border competition matters and rapid integration could reduce competitive dynamics.

A parallel thread runs through the GTCR/Surmodics matter. The FTC challenged the deal in March 2025, arguing that the combined firm would hold a market share exceeding 50% in hydrophilic coatings. The case illustrates a key point: market definition is everything. If regulators define the relevant market aggressively, even a sizable minority overlap can trigger a challenge.

The FTC ultimately rejected the proposed divestiture as insufficient, highlighting that remedies must secure credible competition. For deal teams, this underscores the need for rigorous market mapping and preemptive remedy planning, especially for specialty product areas where a single coating or process can define competitive dynamics.

Synopsys/Ansys also exemplifies the cooperation path regulators sometimes favor. The parties settled with the FTC via divestiture of optical and photonic software tools. This is another reminder that, in complex tech ecosystems, targeted divestitures can preserve momentum while clearing the regulatory path. It isn’t always a full break-up; often it’s a surgical carve-out that preserves strategic value for each party and protects customer choice.

From a practitioner’s view, the HSR landscape in 2025 is a practical tool with teeth. The minimum notification threshold rising to $126.4 million means more mid-market deals will cross the federal radar, and 14 states require pre-merger filings for healthcare transactions. That adds layers of complexity for cross-border or multi-state deals, especially in healthcare where provider markets and patient access have direct public-interest implications. The filing fee increases and the broader state filing regime create a multi-jurisdictional compliance task that must be integrated into deal planning and closing timelines.

In terms of enforcement posture, the data shows a measured but real risk posture. The 184 clearances in FY 2024, split roughly 103 by the FTC and 81 by the DOJ, indicate that both agencies actively review deals, with second requests at 59 across the two agencies. While settlements and divestitures can unlock a deal, the threat of challenging a deal outright remains, and regulators are not shy about using these tools to secure competitive outcomes.

The Trump-era shift toward settlements did not disappear, but it did not become a blanket, all-clear signal either. Practical takeaway: do not rely on settlement-only assumptions; prepare robust remedies and market definitions that stand up to scrutiny.

Case study: comparing two real-world outcomes to extract practical lessons

UniteedHealth/Amedisys: This matter demonstrates how a buyer’s scale and the sensitivity of home health and hospice markets can trigger a deeper look at post-transaction market structure. Regulators focused on care delivery networks and access, leading to a divestiture of 164 locations across 19 states. The remedy is operationally significant but implementable, and it preserves the strategic intent of the deal for UnitedHealth while maintaining competition in essential service areas. The $1.1 million HSR penalty on Amedisys underscores the compliance risk of even seemingly routine filings when the process isn’t followed precisely. For deal teams, the lesson is clear: align compliance teams early, quantify divestiture footprints with operating plans, and validate that remedies effectively preserve competitive constraints before closing.

HPE/Juniper and Keysight/Spirent show how technology overlaps are treated when product lines risk consolidation. In HPE/Juniper, the divestiture of HPE Instant On addresses licensing and product portfolio concerns that could reduce customer choices.

In Keysight/Spirent, divestitures in Ethernet and security testing businesses reflect a focus on preserving competition in critical testing tools that underpin product development cycles. For practitioners, the takeaway is to map product families and testing capabilities to ensure remedies target the right assets and avoid unintended harm to downstream markets or customers.

Takeaways for deal teams

• Build a pre-merger playbook that includes precise market definitions, overlap analysis, and a menu of remedies. Regulators expect thoughtful, credible remedies rather than quick fixes.
• Expect state-level filings in healthcare and other sensitive sectors. Align timelines and costs for multi-jurisdiction reviews.
• Prepare for possible penalties or enforcement actions if reporting failures occur. The Amedisys penalty illustrates that even routine filings carry risk if data accuracy or timing slip.
• Use divestitures strategically. They are often the practical route to clearance; ensure the divestiture scope preserves competitive dynamics and is saleable to independent buyers.
• Document the deal rationale for regulators. Clear articulation of competition-enhancing aspects and how remedies preserve competition helps close deals faster.

Practical notes and next steps

• Verify HSR thresholds and fees early in deal planning. The rise to $126.4 million and the $30,000 fee band affect thresholds, diligence budgets, and potential value drivers.
• Map the regulatory landscape for healthcare and high-tech sectors in particular. Regional filings, product scope, and multi-market effects can drive timing and structure.
• Incorporate a remedies assessment into financial modeling.
• Include potential divestitures, licensing arrangements, and transitional services in closing estimates.
• Stay current on enforcement posture. In 2025, settlements and structural remedies became more common, but regulators still pursued challenges when remedies were inadequate.

If you want more, keep digging into the Matactic glossary. We’ve got terms, real-world examples, and practical checklists to help you navigate antitrust filings in M&A. Sign up for our free M&A course and stay ahead.